Tissue Repair & Regeneration

Palmitoyl Pentapeptide-4 (Matrixyl)

Last updated 12 August 2026

Evidence on file1 randomised human trial · 5 citations not yet graded

Strongest sourceTopical palmitoyl pentapeptide provides improvement in photoaged human facial skin (2005, cited 184x) (randomised human trial)

Manufacturer’s claim vendor marketing

For a proprietary cosmetic ingredient the manufacturer is the originator — there is no upstream to defer to, and this is often the only description that exists. It is reproduced as an attributed claim, with the label its source gave it. It is not graded and it is not evidence — the graded studies are under Literature.

Vendor claim (INCIDecoder, manufacturer-sponsored research): can "reduce fine lines, wrinkles and improve skin texture significantly"; showed "similar wrinkle improving ability" to 0.07% retinol (700 ppm) with "better skin tolerability". n= and duration not stated on fetched page.

Manufacturer: Sederma (in joint effort with Procter & Gamble, per INCIDecoder)
Sold as: Matrixyl (Pal-KTTKS)
Manufacturer’s recommended use: 3 ppm (0.0003%) per INCIDecoder

Source page — nofollow, because a vendor link is a reference here, not an endorsement.

Dosing on file unverified

3 ppm (0.0003%) to 7% serum, 1-2x/day; 0.005% cream; 3 ppm; up to 7% serum

Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.

Literature on file 6

human RCT
Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin (2005, cited 184x) graded on: a randomised study — read from the indexed abstract — “randomized clinical study”

Not graded

5 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

Identity

Space-filling 3D model of Palmitoyl Pentapeptide-4 (Matrixyl), carbon grey, nitrogen blue, oxygen red — Built from the SMILES on this record — the atoms, bonds and stereochemistry are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

2D chemical structure of Palmitoyl Pentapeptide-4 (Matrixyl) — Built from the SMILES on this record — the atoms, bonds and stereochemistry are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

Molecular weight: 802.1
Molecular formula: C39H75N7O10
CAS number: 214047-00-4
PubChem CID: 9897237
InChI key: WSGCRSMLXFHGRM-DEVHWETNSA-N
SMILES: CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O
InChI: InChI=1S/C39H75N7O10/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-23-32(50)42-29(21-17-19-24-40)36(52)45-34(28(3)49)38(54)46-33(27(2)48)37(53)43-30(22-18-20-25-41)35(51)44-31(26-47)39(55)56/h27-31,33-34,47-49H,4-26,40-41H2,1-3H3,(H,42,50)(H,43,53)(H,44,51)(H,45,52)(H,46,54)(H,55,56)/t27-,28-,29+,30+,31+,33+,34+/m1/s1

Also called

Matrixyl
Matrixyl (Palmitoyl Pentapeptide-4)
Palmitoyl Pentapeptide-4

Notes unverified prose

RCT: Robinson et al. 2005 (93 women, 12 weeks, 3 ppm); 0.005% cream (28 days, 18% fold depth reduction); 7% serum (8 weeks, split-face); RCT: 0.005% cream (28 days, crow's feet): fold depth -18%; 12-week split-face RCT (93 women, 3 ppm): significant wrinkle reduction; 8-week (43 women, 50-70); Robinson et al. 2005 RCT (93 women, 12 weeks)

Not on file 1

1 of the 8 fields we track hold nothing on this record, and each says why. A blank field is a bug; a named absence is a finding.

amino-acid sequencenothing we hold supplies it

Each field links to every other record missing the same thing. The full ledger holds 521 gaps across 136 records.